← ANALYST RATINGS · TIPRANKS
Niagen Bioscience (NAGE): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $10.50, the highest $11.00, the lowest $10.00. The average is +321.7% from the last price of $2.49.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Sean McGowan★★★★★★★★★★#9856 · hits 35% · avg −0.8% | Roth MKM | $10.00 | Buy | +301.6% | Reiterated | 12.10.26on TipRanks 08:10 | −2.2%next day −1.9% | ↗ |
| Susan Anderson★★★★★★★★★★#576 · hits 45% · avg +16.7% | Canaccord Genuity | $10.00 | Buy | +301.6% | Reiterated | 05.10.26on TipRanks 07:16 | −4.6%next day −0.2% · 5 days −2.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Buy | +20.5% | Reiterated | 02.10.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | +20.5% | Reiterated | 02.10.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | +20.5% | Reiterated | 02.10.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Hold | +20.5% | Reiterated | 02.10.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Buy | +20.5% | Reiterated | 02.10.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | +20.5% | Downgrade | 02.10.26on TipRanks 12:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $11.00 | Buy | +341.8% | Reiterated | 05.08.26on TipRanks 06:16 | −14.5%next day +2.9% · 5 days +3.0% | ↗ |
| Jeffrey Cohen★★★★★★★★★★#11115 · hits 35% · avg −2.9% | Ladenburg Thalmann & Co. | $12.00 → $11.00−8.3% | Buy | +341.8% | Reiterated | 21.07.26on TipRanks Jul 24 21:24 | +2.7%next day −2.6% · 5 days −4.7% | ↗ |
| Ilya Zubkov★★★★★★★★★★#5009 · hits 59% · avg +9.5% | Freedom Capital Markets | $9.00 | Buy | +261.4% | Initiated | 06.07.26on TipRanks 15:15 | +1.2%next day −1.0% · 5 days −0.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Niagen Bioscience
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.20 at a price of $2.92 (+249.3%); now: $10.50 at $2.49 (+321.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 6 | 10 | 10 | 12 | 9 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.01 (from $-0.03 to $0.06). Last quarter: $0.01.
Sales
Next quarter’s sales estimate — $34M (from $27M to $38M). Last quarter: $30M.
Best top-analyst consensus in the sector · Consumerdefensive
About Niagen Bioscience
- CEO: Robert N. Fried
- Employees: 117
- 10900 Wilshire Blvd, Suite 600, Los Angeles, CA, 90024, US
- www.niagenbioscience.com
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Data from the stock’s TipRanks forecast page, read 62 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗